Biofarm (BSE:BIO) Piotroski F-Score: 7 (As of Jul. 07, 2026) — 17% Above Median


BSE:BIO Biofarm SA BSE:BIO
69 GF Score
Price lei1.37
GF Value lei0.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofarm Piotroski F-Score?

Biofarm BSE:BIO +0.37% 69 Piotroski F-Score is 7 as of Jul. 07, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates BSE:BIO with a GF Score™ of 69/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Biofarm ranks better than 91.95% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biofarm has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Biofarm's Piotroski F-Score or its related term are showing as below:

BSE:BIO' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Biofarm was 9. The lowest was 4. And the median was 6.

Biofarm  (BSE:BIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biofarm Piotroski F-Score Related Terms


Biofarm Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Biofarm's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Piotroski F-Score Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.00 7.00 5.00 4.00 7.00

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 8.00 6.00 7.00 7.00

BSE:BIO vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofarm Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofarm's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biofarm's Piotroski F-Score falls into.


BSE:BIO
69GF Score
Biofarm SA BSE:BIO
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 16.485 + 38.253 + 13.57 + 32.532 = lei100.8 Mil.
Cash Flow from Operations was 37.689 + 28.637 + -13.952 + 40.16 = lei92.5 Mil.
Revenue was 67.829 + 100.353 + 56.073 + 92.491 = lei316.7 Mil.
Gross Profit was 61.049 + 84.042 + 49.788 + 78.543 = lei273.4 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(589.375 + 588.942 + 615.771 + 636.873 + 676.741) / 5 = lei621.5404 Mil.
Total Assets at the begining of this year (Mar25) was lei589.4 Mil.
Long-Term Debt & Capital Lease Obligation was lei1.1 Mil.
Total Current Assets was lei464.2 Mil.
Total Current Liabilities was lei94.2 Mil.
Net Income was 21.372 + 31.263 + 1.143 + 32.325 = lei86.1 Mil.

Revenue was 69.641 + 89.978 + 55.629 + 95.08 = lei310.3 Mil.
Gross Profit was 59.912 + 75.434 + 47.199 + 78.011 = lei260.6 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(508.112 + 526.096 + 546.603 + 555.481 + 589.375) / 5 = lei545.1334 Mil.
Total Assets at the begining of last year (Mar24) was lei508.1 Mil.
Long-Term Debt & Capital Lease Obligation was lei1.0 Mil.
Total Current Assets was lei360.7 Mil.
Total Current Liabilities was lei77.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biofarm's current Net Income (TTM) was 100.8. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biofarm's current Cash Flow from Operations (TTM) was 92.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=100.84/589.375
=0.1710965

ROA (Last Year)=Net Income/Total Assets (Mar24)
=86.103/508.112
=0.16945673

Biofarm's return on assets of this year was 0.1710965. Biofarm's return on assets of last year was 0.16945673. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biofarm's current Net Income (TTM) was 100.8. Biofarm's current Cash Flow from Operations (TTM) was 92.5. ==> 92.5 <= 100.8 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1.134/621.5404
=0.0018245

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1.013/545.1334
=0.00185826

Biofarm's gearing of this year was 0.0018245. Biofarm's gearing of last year was 0.00185826. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=464.168/94.221
=4.92637522

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=360.651/77.219
=4.6704956

Biofarm's current ratio of this year was 4.92637522. Biofarm's current ratio of last year was 4.6704956. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biofarm's number of shares in issue this year was 985.375. Biofarm's number of shares in issue last year was 985.375. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=273.422/316.746
=0.86322164

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=260.556/310.328
=0.83961486

Biofarm's gross margin of this year was 0.86322164. Biofarm's gross margin of last year was 0.83961486. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=316.746/589.375
=0.53742694

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=310.328/508.112
=0.61074724

Biofarm's asset turnover of this year was 0.53742694. Biofarm's asset turnover of last year was 0.61074724. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biofarm has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Biofarm (BSE:BIO) has a Piotroski F-Score of 7 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Biofarm and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Biofarm's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, Biofarm ranks #79 out of 981 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Biofarm's Piotroski F-Score too high?
Biofarm's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Biofarm's value of 7 is 40% above this industry median. Based on the distribution chart, Biofarm ranks #79 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofarm has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #79 out of 981 companies for Piotroski F-Score. This places Biofarm in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Biofarm's value of 7 is 40% above this benchmark. Historically, Biofarm's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.37 — trading 57.5% above its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Drug Manufacturers industry median of 5.00. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current Piotroski F-Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.37 is trading 57.5% above its estimated GF Value™ of lei0.87. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: lei0.87 vs. price of lei1.37 (57.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs
  • Industry Position: 40% above the Drug Manufacturers median (#79 of 981)

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for BSE:BIO

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.37
Price
lei0.87
GF Value